Best practice in the use of natalizumab in multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 6, Issue 2, 2013, Pages 69-79

  Fernandez, Oscar ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy; risk stratification

Indexed keywords

ANTIVIRUS AGENT; BETA INTERFERON; CORTICOSTEROID; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MIRTAZAPINE; NATALIZUMAB; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN 2A ANTAGONIST;

ADOLESCENT DISEASE; ASTHENIA; BREAST CANCER; CHILDHOOD DISEASE; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GOOD CLINICAL PRACTICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFUSION RELATED REACTION; MELANOMA; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; TREATMENT DURATION; UTERINE CERVIX CANCER;

EID: 84874476843     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285612470401     Document Type: Review

References (47)

1. Appleton R. Boggild M. (2009) Natalizumab in paediatric multiple sclerosis and service implication. Dev Med Child Neurol 51: 758–759.
2. Baron J. Madri J. Ruddle N. Hashim G. Janeway C. (1993) Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177: 57–68.
3. Berger J. Major E. (2008) Progressive multifocal leukoencephalopathy. Semin Neurol 19: 193–200.
4. Bloomgren G. Richman S. Hotermans C. Subramanyam M. Goelz S. Natarajan A. et al. (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366: 1870–1880.
5. Bozic C. Richman S. Plavina T. Natarajan A. Scanlon J. Subramanyam M. et al. (2011) Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 70: 742-750.
6. Calabresi P. Giovannoni G. Confavreux C. Galetta S. Havrdova E. Hutchinson M. et al. (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69: 1391–1403.
7. Coyle P. Foley J. Fox E. Jeffery D. Munschauer F. III Tornatore C. (2009) Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy. Mult Scler 15(Suppl. 4): S26-S36.
8. Cree B. de Seze J. Fox R. Gold R. Hartung H. Jeffery D. et al. (2012) Study: effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis magnetic resonance imaging disease activity. Poster Presented at the American Academy of Neurology 64th Annual Meeting, New Orleans, LA.
9. Fernández O. Alvarenga M. Guerrero M. León A. Alonso A. López-Madrona et al. (2011 a) The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Mult Scler 17: 192–197.
10. Fernández O. García-Merino J. Arroyo R. Alvarez-Cermeño J. Arbizu T. Izquierdo G. et al. (2011 b) Spanish consensus on the use of natalizumab (Tysabri(®)) - 2011. Neurologia (Barcelona, Spain) [ePub ahead of print], PMID: 22078648.
11. Fernández O. Oreja-Guevara C. Arroyo R. Izquierdo G. Pérez J. Montalban X. (2012) Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol [Epub ahead of print], PMID: 22289966.
12. Fox R. Kappos L. Cree B. Kaufman M. Jeffery D. Weinstock-Guttman B. et al. (2011) Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: The RESTORE study. In: Late Breaking News. Presented at the European Committee for the Treatment and Research in Multiple Sclerosis 27th Annual Meeting, Amsterdam, the Netherlands.
13. Gorelik L. Lerner M. Bixler S. Crossman M. Schlain B. Simon K. et al. (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68: 295–303.
14. Horga A. Castillo J. Rio J. Tintore M. Auger C. Sastre-Garriga J. et al. (2011) An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev Neurol 52: 321-330.
15. Huppke P. Stark W. Zürcher C. Huppke B. Brück W. Gärtner J. (2008) Natalizumab use in pediatric multiple sclerosis. Arch Neurol 65: 1655–1658.
16. Hurley R. Ernst T. Khalili K. Del Valle L. Simone I. Taber K. (2003) Identification of HIV-associated progressive multifocal leukoencephalopathy: magnetic resonance imaging and spectroscopy. J Neuropsychiatry Clin Neurosci 15: 1–6.
17. Kappos L. Bates D. Edan G. Eraksoy M. Garcia-Merino A. Grigoriadis N. et al. (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10: 745–758.
18. Kappos L. Bates D. Hartung H. Havrdova E. Miller D. Polman C. et al. (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6: 431–441.
19. Kappos L. Belachew S. Butzkueven H. Pellegrini F. Trojano M. Wiendl H., et al. et al (2012) Long-term safety and efficacy and association between baseline treatment history and postbaseline relapses in multiple sclerosis patients treated with natalizumab in the TYSABRI® Observational Program (TOP). Poster 4.134 presented at the American Academy of Neurology 64th Annual Meeting, New Orleans, LA.
20. Krumbholz M. Pellkofer H. Gold R. Hoffmann L. Hohlfeld R. Kümpfel T. (2007) Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 64: 1331–1333.
21. Léger O. Yednock T. Tanner L. Horner H. Hines D. Keen S. et al. (1997) Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 8: 3–16.
22. Mancardi G. Tedeschi G. Amato M. D'Alessandro R. Drago F. Milanese C. et al. (2011) Three years of experience: the Italian registry and safety data update. Neurol Sci 31(Suppl. 3): 295-297.
23. Mateen F. Muralidharan R. Carone M. van de Beek D. Harrison D. Aksamit A. et al. (2011) Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 70: 305–322.
24. Miller D. Khan O. Sheremata W. Blumhardt L. Rice G. Libonati M. et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15–23.
25. O'Connor P. Goodman A. Kappos L. Lublin F. Miller D. Polman C. et al. (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76: 1858-1865.
26. O'Connor P. Miller D. Riester K. Yang M. Panzara M. Dalton C. et al. (2005) Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult Scler 11: 568–572.
27. Oliver B. Fernández O. Orpez T. Alvarenga M. Pinto-Medel M. Guerrero M. et al. (2011) Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. Mult Scler 17: 368–371.
28. Oturai A. Koch-Henriksen N. Petersen T. Jensen P. Sellebjerg F. Sorensen P. (2009) Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 16: 420–423.
29. Outteryck O. Ongagna J. Duhamel A. Zéphir H. Collongues N. Lacour A. et al. (2012) Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol [ePub ahead of print], PMID: 22527227.
30. Outteryck O. Ongagna J. Zéphir H. Fleury M. Lacour A. Blanc F. et al. (2010) Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 257: 207–211.
31. Piehl F. Holmén C. Hillert J. Olsson T. (2011) Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci 31(Suppl. 3): 289–293.
32. Polman C. O'Connor P. Havrdova E. Hutchinson M. Kappos L. Miller D. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910.
33. Prosperini L. Borriello G. Fubelli F. Marinelli F. Pozzilli C. (2011) Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci [ePub ahead of print], PMID: 20535513.
34. Putzki N. Yaldizli O. Bühler R. Schwegler G. Curtius D. Tettenborn B. (2010 a) Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol 63: 101–106.
35. Putzki N. Yaldizli O. Mäurer M. Cursiefen S. Kuckert S. Klawe C. et al. (2010 b) Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 17: 31–37.
36. Rudick R. Stuart W. Calabresi P. Confavreux C. Galetta S. Radue E. et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911–923.
37. Sangalli F. Moiola L. Bucello S. Annovazzi P. Rizzo A. Radaelli M. et al. (2011) Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci [ePub ahead of print], PMID: 20544247.
38. Stüve O. Cravens P. Frohman E. Phillips J. Remington G. von Geldern G. et al. (2009) Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 72: 396–401.
39. Tan I. McArthur J. Clifford D. Major E. Nath A. (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77: 1061–1067.
40. Tan K. Roda R. Ostrow L. McArthur J. Nath A. (2009) PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72: 1458–1464.
41. Trampe A. Hemmelmann C. Stroet A. Haghikia A. Hellwig K. Wiendl H. et al. (2012) Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 78: 1736–1742.
42. Tur C. Tintoré M. Vidal-Jordana A. Castilló J. Galán I. Río J. et al. (2012) Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. Mult Scler [ePub ahead of print], PMID: 22383232.
43. van Assche G. van Ranst M. Sciot R. Dubois B. Vermeire S. Noman M. et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362–368.
44. Wenning W. Haghikia A. Laubenberger J. Clifford D. Behrens P. Chan A. et al. (2009) Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361: 1075-1080.
45. West T. Cree B. (2010) Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 68: 395–399.
46. Yeh E. Weinstock-Guttman B. (2010) Natalizumab in pediatric multiple sclerosis patients. Ther Adv Neurol Disord 3: 293-299.
47. Yousry T. Major E. Ryschkewitsch C. Fahle G. Fischer S. Hou J. et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924–933.